GenMark Diagnostics Plans to Expand Test Menu, Develop Automated Next-Gen System

The company plans to launch an assay to detect sensitivity to the anticoagulant Plavix and another to detect KRAS mutations predictive of response to the cancer therapies Erbitux and Vectibix.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.